The role of adenosine receptors A 2A and A 2B signaling in renal fibrosis

Kidney International

Volumn 86, Issue 4, 2014, Pages 685-692

  Roberts, Veena S ^a   Cowan, Peter J ^a   Alexander, Stephen I ^b   Robson, Simon C ^c   Dwyer, Karen M ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b CHILDREN S HOSPITAL AT WESTMEAD   (Australia)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

cell signaling; chronic renal disease; fibrosis; inflammation; renal fibrosis

Indexed keywords

2 [4 (2 CARBOXYETHYL)PHENETHYLAMINO]ADENOSINE 5' (N ETHYLCARBOXAMIDE); 4 [2 [7 AMINO 2 (2 FURYL) 1,2,4 TRIAZOLO[2,3 A][1,3,5]TRIAZIN 5 YLAMINO]ETHYL]PHENOL; 5' NUCLEOTIDASE; ADENOSINE; ADENOSINE A2A RECEPTOR; ADENOSINE A2A RECEPTOR ANTAGONIST; ADENOSINE A2B RECEPTOR; ADENOSINE DEAMINASE; ADENOSINE DIPHOSPHATE; ADENOSINE RECEPTOR; ALPHA SMOOTH MUSCLE ACTIN; ANGIOTENSIN II; APADENOSON; CD11B ANTIGEN; CD39 ANTIGEN; CONNECTIVE TISSUE GROWTH FACTOR; CYCLIC AMP; ENDOTHELIN 1; EQUILIBRATIVE NUCLEOSIDE TRANSPORTER 1; EQUILIBRATIVE NUCLEOSIDE TRANSPORTER 2; GUANINE NUCLEOTIDE BINDING PROTEIN ALPHA SUBUNIT; N (4 CYANOPHENYL) 2 [4 (2,3,6,7 TETRAHYDRO 2,6 DIOXO 1,3 DIPROPYL 1H PURIN 8 YL)PHENOXY]ACETAMIDE; PLATELET DERIVED GROWTH FACTOR; PSB 1115; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; VASCULOTROPIN; ADENOSINE TRIPHOSPHATASE; APYRASE; ECTOATPASE; LEUKOCYTE ANTIGEN; NUCLEOSIDE TRIPHOSPHATE DIPHOSPHOHYDROLASE 8, HUMAN;

ADENOSINE DEAMINASE DEFICIENCY; ADOPTIVE TRANSFER; ANIMAL CELL; ANTIGEN EXPRESSION; AUTOCRINE EFFECT; CALCIUM MOBILIZATION; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL INFILTRATION; CONTROLLED STUDY; DIABETIC NEPHROPATHY; DISEASE COURSE; EXOCYTOSIS; EXTRACELLULAR MATRIX; GLOMERULOSCLEROSIS; HYDROLYSIS; KIDNEY FIBROSIS; KIDNEY INJURY; MESANGIUM CELL; MOUSE; NEPHRITIS; NEPHROSCLEROSIS; NONHUMAN; PARACRINE SIGNALING; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; RECEPTOR BINDING; REGULATORY T LYMPHOCYTE; RENAL PROTECTION; REVIEW; SCID MOUSE; SIGNAL TRANSDUCTION; URETER OBSTRUCTION; VASOCONSTRICTION; ANIMAL; CHRONIC KIDNEY FAILURE; FIBROBLAST; FIBROSIS; HUMAN; KIDNEY; MACROPHAGE; METABOLISM; PATHOLOGY;

ADENOSINE; ADENOSINE TRIPHOSPHATASES; ANIMALS; ANTIGENS, CD; APYRASE; AUTOCRINE COMMUNICATION; FIBROBLASTS; FIBROSIS; HUMANS; KIDNEY; MACROPHAGES; PARACRINE COMMUNICATION; RECEPTOR, ADENOSINE A2A; RECEPTOR, ADENOSINE A2B; RENAL INSUFFICIENCY, CHRONIC; SIGNAL TRANSDUCTION;

EID: 84926226771     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2014.244     Document Type: Review

References (84)

1. Venkatachalam MA, Griffin KA, Lan R et al. Acute kidney injury: a springboard for progression in chronic kidney disease. Am J Physiol Renal Physiol 2010; 298: F1078-F1094.
2. Basile DP, Donohoe DL, Roethe K. Chronic renal hypoxia after acute ischemic injury: effects of l-arginine on hypoxia and secondary damage. Am J Physiol Renal Physiol 2003; 284: F338-F348.
3. Nangaku M. Chronic hypoxia and tubulointerstitial injury: a final common pathway to end-stage renal failure. J Am Soc Nephrol 2006; 17: 17-25.
4. Fine LG. Chronic hypoxia as a mechanism of progression of chronic kidney diseases: from hypothesis to novel therapeutics. Kidney Int 2008; 74: 867-872.
5. Eltzschig HK, Carmeliet P. Hypoxia and inflammation. N Engl J Med 2011; 364: 656-665.
6. Bauerle JD, Grenz A, Kim J-H et al. Adenosine generation and signaling during acute kidney injury. J Am Soc Nephrol 2011; 22: 14-20.
7. Eltzschig HK. Adenosine: an old drug newly discovered. Anesthesiology 2009; 111: 904-915.
8. Cronstein BN. Adenosine receptors and fibrosis: a translational review. F1000 Biol Rep 2011; 3: 21.
9. Fredholm BB. Adenosine, an endogenous distress signal, modulates tissue damage and repair. Cell Death Differ 2007; 14: 1315-1323.
10. Chan ES, Fernandez P, Merchant AA et al. Adenosine A2A receptors in diffuse dermal fibrosis: pathogenic role in human dermal fibroblasts and in a murine model of scleroderma. Arthritis Rheum 2006; 54: 2632-2642.
11. Schneider DJ, Lindsay JC, Zhou Y et al. Adenosine and osteopontin contribute to the development of chronic obstructive pulmonary disease. FASEB J 2010; 24: 70-80.
12. Chan ESL, Montesinos MC, Fernandez P et al. Adenosine A2A receptors play a role in the pathogenesis of hepatic cirrhosis. Br J Pharmacol 2006; 148: 1144-1155.
13. Künzli BM, Nuhn P, Enjyoji K et al. Disordered pancreatic inflammatory responses and inhibition of fibrosis in CD39-null mice. Gastroenterology 2008; 134: 292-305.
14. Wakeno M, Minamino T, Seguchi O et al. Long-term stimulation of adenosine A2b receptors begun after myocardial infarction prevents cardiac remodeling in rats. Circulation 2006; 114: 1923-1932.
15. Dubey RK, Gillespie DG, Zacharia LC et al. A(2b) receptors mediate the antimitogenic effects of adenosine in cardiac fibroblasts. Hypertension 2001; 37(2 Pt 2): 716-721.
16. Vallon V, Mühlbauer B, Osswald H. Adenosine and kidney function. Physiol Rev 2006; 86: 901-940.
17. Ponnusamy M, Ma L, Gong R et al. P2X7 receptors mediate deleterious renal epithelial-fibroblast cross talk. Am J Physiol Renal Physiol 2011; 300: F62-F70.
18. Zarjou A, Agarwal A. ATP as a death factor: purinergic signaling in renal epithelial-fibroblast cross talk. Am J Physiol Renal Physiol 2011; 300: F60.
19. Fredholm BB IA, Jacobson KA, Klotz KN et al. International Union of Pharmacology. XXV. Nomenclature and classification of adenosine receptors. Pharmacol Rev 2001; 53: 527.
20. Blackburn M, Vance C, Morschl E et al. Adenosine receptors and inflammation. In: Wilson CN, Mustafa SJ editors. Adenosine Receptors in Health and Disease. Handbook of Experimental Pharmacology. 193. Springer: Berlin Heidelberg, 2009 p 215-269.
21. Robson S, Vigny JS, Zimmermann H. The E-NTPDase family of ectonucleotidases: structure function relationships and pathophysiological significance. Purinergic Signal 2006; 2: 409-430.
22. Kishore BK, Isaac J, Fausther M et al. Expression of NTPDase1 and NTPDase2 in murine kidney: relevance to regulation of P2 receptor signaling. Am J Physiol Renal Physiol 2005; 288: F1032-F1043.
23. Vekaria RM, Shirley DG, Sévigny J et al. Immunolocalization of ectonucleotidases along the rat nephron. Am J Physiol Renal Physiol 2006; 290: F550-F560.
24. Le Hir M, Kaissling B. Distribution and regulation of renal ecto-5'-nucleotidase: implications for physiological functions of adenosine. Am J Physiol Renal Physiol 1993; 264: F377-F387.
25. Lee HT, Emala CW. Adenosine attenuates oxidant injury in human proximal tubular cells via A1 and A2a adenosine receptors. Am J Physiol Renal Physiol 2002; 282: F844-F852.
26. Zhang W, Zhang Y, Wang W et al. Elevated CD73-mediated increased renal adenosine signaling via A2B adenosine receptor contributes to chronic hypertension. Circ Res 2013; 112: 1466-1478.
27. Boor P, Ostendorf T, Floege J. Renal fibrosis: novel insights into mechanisms and therapeutic targets. Nat Rev Nephrol 2010; 6: 643-656.
28. Wynn TA, Ramalingam TR. Mechanisms of fibrosis: therapeutic translation for fibrotic disease. Nat Med 2012; 18: 1028-1040.
29. Özüyaman B, Ding Z, Buchheiser A et al. Adenosine produced via the CD73/ecto-50-nucleotidase pathway has no impact on erythropoietin production but is associated with reduced kidney weight. Pflugers Arch 2006; 452: 324-331.
30. Blume C, Felix A, Shushakova N et al. Autoimmunity in CD73/Ecto-59-nucleotidase deficient mice induces renal injury. PLoS ONE 2012; 7: e37100.
31. Anders HJ, Ryu M. Renal microenvironments and macrophage phenotypes determine progression or resolution of renal inflammation and fibrosis. Kidney Int 2011; 80: 915-925.
32. Cao Q, Wang Y, Harris DCH. Pathogenic and protective role of macrophages in kidney disease. Am J Physiol Renal Physiol 2013; 305: F3-F11.
33. Lee S, Huen S, Nishio H et al. Distinct macrophage phenotypes contribute to kidney injury and repair. J Am Soc Nephrol 2011; 22: 317-326.
34. Bours MJL, Swennen ELR, Di Virgilio F et al. Adenosine 50-triphosphate and adenosine as endogenous signaling molecules in immunity and inflammation. Pharmacol Ther 2006; 112: 358-404.
35. Sakaki H, Tsukimoto M, Harada H et al. Autocrine regulation of macrophage activation via exocytosis of ATP and activation of P2Y11 receptor. PLoS ONE 2013; 8: e59778.
36. Lévesque SA, Kukulski F, Enjyoji K et al. NTPDase1 governs P2X7-dependent functions in murine macrophages. Eur J Immunol 2010; 40: 1473-1485.
37. Kreckler LM, Wan TC, Ge ZD et al. Adenosine inhibits tumor necrosis factor-alpha release from mouse peritoneal macrophages via A2A and A2B but not the A3 adenosine receptor. J Pharmacol Exp Ther 2006; 317: 172-180.
38. Haskó G, Pacher P. Regulation of macrophage function by adenosine. Arterioscler Thromb Vasc Biol 2012; 32: 865-869.
39. Hasko G, Pacher P, Deitch EA et al. Shaping of monocyte and macrophage function by adenosine receptors. Pharmacol Ther 2007; 113: 264-275.
40. Csó ka B, Selmeczy Z, Koscsó B et al. Adenosine promotes alternative macrophage activation via A2A and A2B receptors. FASEB J 2012; 26: 376-386.
41. Cohen HB, Briggs KT, Marino JP et al. TLR stimulation initiates a CD39-based autoregulatory mechanism that limits macrophage inflammatory responses. Blood 2013; 122: 1935-1945.
42. Ferrante C, Pinhal-Enfield G, Elson G et al. The adenosine-dependent angiogenic switch of macrophages to an M2-like phenotype is independent of interleukin-4 receptor alpha (IL-4Ra) signaling. Inflammation 2013; 36: 921-931.
43. Eardley KS, Kubal C, Zehnder D et al. The role of capillary density, macrophage infiltration and interstitial scarring in the pathogenesis of human chronic kidney disease. Kidney Int 2008; 74: 495-504.
44. Garcia GE. Adenosine A2A receptor activation prevents progressive kidney fibrosis in a model of immune-associated chronic inflammation. Kidney Int 2011; 80: 378-388.
45. Awad AS, Huang L, Ye H et al. Adenosine A2A receptor activation attenuates inflammation and injury in diabetic nephropathy. Am J Physiol Renal Physiol 2006; 290: F828-F837.
46. Tapmeier TT, Fearn A, Brown K et al. Pivotal role of CD4- T cells in renal fibrosis following ureteric obstruction. Kidney Int. 2010; 78: 351-362.
47. Deaglio S, Dwyer K, Gao W et al. Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression. J Exp Med 2007; 204: 1257-1265.
48. Xiao H, Si L-Y, Liu W et al. The effects of adenosine A2A receptor knockout on renal interstitial fibrosis in a mouse model of unilateral ureteral obstruction. Acta Histochem 2013; 115: 315-319.
49. Xiao H, Shen HY, Liu W et al. Adenosine A2A receptor: a target for regulating renal interstitial fibrosis in obstructive nephropathy. PLoS ONE 2013; 8: e60173.
50. Mahajan D, Wang Y, Qin X et al. CD4CD25 regulatory T cells protect against injury in an innate murine model of chronic kidney disease. J Am Soc Nephrol 2006; 17: 2731-2741.
51. Wang YM, McRae JL, Robson SC et al. Regulatory T cells participate in CD39-mediated protection from renal injury. Eur J Immunol 2012; 42: 2441-2451.
52. Feoktistov I, Biaggioni I. Chapter 5-Role of adenosine A2B receptors in inflammation. In: Kenneth AJ, Joel L editors. Advances in pharmacology Vol 61, Elsevier Academic Press: Kansas City, 2011, p 115-144.
53. Fredholm BB, IJzerman AP, Jacobson KA et al. International Union of Basic and Clinical Pharmacology. LXXXI. Nomenclature and classification of adenosine receptors-an update. Pharmacol Rev 2011; 63: 1-34.
54. Nath K. Tubulointerstitial changes as a major determinant in the progression of renal damage. Am J Kidney Dis 1992; 20: 1-17.
55. Lin S-L, Kisseleva T, Brenner DA et al. Pericytes and perivascular fibroblasts are the primary source of collagen-producing cells in obstructive fibrosis of the kidney. Am J Pathol 2008; 173: 1617-1627.
56. Kilarski WW, Samolov B, Petersson L et al. Biomechanical regulation of blood vessel growth during tissue vascularization. Nat Med 2009; 15: 657-664.
57. Boor P, Floege J. The renal (myo-)fibroblast: a heterogeneous group of cells. Nephrol Dial Transplant 2012; 27: 3027-3036.
58. Schlöndorff D, Banas B. The mesangial cell revisited: no cell is an island. J Am Soc Nephrol 2009; 20: 1179-1187.
59. Moura IC, Benhamou M, Launay P et al. The glomerular response to IgA deposition in IgA nephropathy. Semin Nephrol 2008; 28: 88-95.
60. Ross R, Everett NB, Tyler R. Wound healing and collagen formation: VI. The origin of the wound fibroblast studied in parabiosis. J Cell Biol 1970; 44: 645-654.
61. Ekblom P, Weller A. Ontogeny of tubulointerstitial cells. Kidney Int 1991; 39: 394-400.
62. Iwano M, Plieth D, Danoff TM et al. Evidence that fibroblasts derive from epithelium during tissue fibrosis. J Clin Invest 2002; 110: 341.
63. Kriz W, Kaissling B, Le Hir M. Epithelial-mesenchymal transition (EMT) in kidney fibrosis: fact or fantasy? J Clin Invest 2011; 121: 468-474.
64. Grgic I, Duffield J, Humphreys B. The origin of interstitial myofibroblasts in chronic kidney disease. Pediatr Nephrol 2012; 27: 183-193.
65. Schrimpf C, Xin C, Campanholle G et al. Pericyte TIMP3 and ADAMTS1 modulate vascular stability after kidney injury. J Am Soc Nephrol 2012; 23: 868-883.
66. Dai Y, Zhang W, Wen J et al. A2B adenosine receptor-mediated induction of IL-6 promotes CKD. JAm Soc Nephrol 2011; 22: 890-901.
67. Zhong H, Belardinelli L, Maa T et al. Synergy between A2B adenosine receptors and hypoxia in activating human lung fibroblasts. Am J Respir Cell Mol Biol 2005; 32: 2-8.
68. Yang J, Chen J, Yan J et al. Effect of interleukin 6 deficiency on renal interstitial fibrosis. PLoS ONE 2012; 7: e52415.
69. Kim M, Ham A, Kim JY et al. The volatile anesthetic isoflurane induces ecto-5-nucleotidase (CD73) to protect against renal ischemia and reperfusion injury. Kidney Int 2013; 84: 90-103.
70. Zager RA, Johnson ACM, Andress D et al. Progressive endothelin-1 gene activation initiates chronic/end-stage renal disease following experimental ischemic/reperfusion injury. Kidney Int 2013; 84: 703-712.
71. Remuzzi G, Bertani T. Pathophysiology of progressive nephropathies. N Engl J Med 1998; 339: 1448-1456.
72. Karczewska J, Piwkowska A, Rogacka D et al. Purinergic modulation of glucose uptake into cultured rat podocytes: effect of diabetic milieu. Biochem Biophys Res Commun 2011; 404: 723-727.
73. Roa H, Gajardo C, Troncoso E et al. Adenosine mediates transforming growth factor-beta 1 release in kidney glomeruli of diabetic rats. FEBS Lett 2009; 583: 3192-3198.
74. Tak E, Ridyard D, Kim J-H et al. CD73-dependent generation of adenosine and endothelial Adora2b signaling attenuate diabetic nephropathy. J Am Soc Nephrol 2014; 25: 547-563.
75. Pawelczyk T, Podgorska M, Sakowicz M. The effect of insulin on expression level of nucleoside transporters in diabetic rats. Mol Pharmacol 2003; 63: 81-88.
76. Makino H, Miyamoto Y, Sawai K et al. Altered gene expression related to glomerulogenesis and podocyte structure in early diabetic nephropathy of db/db mice and its restoration by pioglitazone. Diabetes 2006; 55: 2747-2756.
77. Kong T, Westerman KA, Faigle M et al. HIF-dependent induction of adenosine A2B receptor in hypoxia. FASEB J 2006; 20: 2242-2250.
78. Valladares D, Quezada C, Montecinos P et al. Adenosine A2B receptor mediates an increase on VEGF-A production in rat kidney glomeruli. Biochem Biophys Res Commun 2008; 366: 180-185.
79. Barnes JL, Gorin Y. Myofibroblast differentiation during fibrosis: role of NAD(P)H oxidases. Kidney Int 2011; 79: 944-956.
80. Cardenas A, Toledo C, Oyarzun C et al. Adenosine A2B receptor-mediated VEGF induction promotes diabetic glomerulopathy. Lab Invest 2013; 93: 135-144.
81. Hinz S, Lacher SK, Seibt B et al. BAY60-6583 acts as a partial agonist at adenosine A2B receptors. J Pharmacol Exp Ther 2014; 349: 427-436.
82. Xia J-F, Liang Q-L, Hu P et al. Correlations of six related purine metabolites and diabetic nephropathy in Chinese type 2 diabetic patients. Clin Biochem 2009; 42: 215-220.
83. Friedman DJ, Talbert ME, Bowden DW et al. Functional ENTPD1 polymorphisms in African Americans with diabetes and end-stage renal disease. Diabetes 2009; 58: 999-1006.
84. Friedman DJ, Rennke HG, Csizmadia E et al. The vascular ectonucleotidase ENTPD1 is a novel renoprotective factor in diabetic nephropathy. Diabetes 2007; 56: 2371-2379.